



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/679,896	10/05/2000	Soon Sun Shim	1293.114RE	7637

21171 7590 11/28/2007
STAAS & HALSEY LLP
SUITE 700
1201 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005

EXAMINER

TOPGYAL, GELEK W

ART UNIT	PAPER NUMBER
----------	--------------

2621

MAIL DATE	DELIVERY MODE
-----------	---------------

11/28/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
09679896	10/5/2000	SHIM, SOON SUN	1293.114RE

STAAS & HALSEY LLP
SUITE 700
1201 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005

EXAMINER

Gelek Topgyal


ART UNIT	PAPER
2621	20071121

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

A review of the file finds that a Notice of Non-Compliance (37 CFR 1.121) was mailed in the instant reissue application on 10/27/03 for applicant's failure to provide a complete listing of all claims. As noted in the Response to the Notice of Non-Compliance filed by applicant on 10/31/07, only 37 CFR 1.121(i) pertains to reissue applications. Rather, any issues of non-compliance should have been noted with respect to CFR 1.173 (amendment practice for reissue). Accordingly, the Notice of Non-Compliance mailed 10/27/03 is hereby vacated. The Office apologize for any inconvenience to applicant. Should the examiner notice any deficiencies in amendment format with respect to 37 CFR 1.173, they will be noted in the next Office action. No further response is required at this time as an action on the merits is forthcoming.


THAI OATRAN
SUPERVISORY PATENT EXAMINER
BIOLOGY CENTER 2300